Our Science

BEYOND IDIOPATHIC, ETIOLOGY REVEALED

Across age-related diseases, a substantial proportion of patients are classified as idiopathic. A growing body of evidence indicates that, in these cases, disease often reflects dysfunction at the level of one or more hallmarks of aging. Clinical translation of this understanding has been limited by the absence of measurement tools that are scalable, reproducible and accessible in clinical settings.

BEYOND GENOMiX is developing such tools, enabling the assessment of the hallmarks of aging in clinical practice and the identification of etiology in idiopathic disease.

A NEW CLINICAL DIMENSION

Until recently, the hallmarks of aging could only be studied in research settings, in isolated systems, on small cohorts, with tools that did not scale into clinical practice. Convergent advances in single-cell biology, photonics, miniaturized sampling and machine learning are extending what can be measured. For the first time, aging biology can be captured at high resolution, in clinical samples, in its native context.

BEYOND GENOMiX is building the platform that brings this dimension into clinical reach, translating aging biology into structured insight, proprietary diagnostics and clinical data assets relevant to pharmaceutical R&D.

SCIENTIFIC FOCUS

BEYOND GENOMiX has developed a measurement-first platform focused on four essential areas.

01MEASUREMENT

We develop proprietary, high-resolution measurement tools for the hallmarks of aging, operating on minimal sample input. Our platform was founded on telomere biology, where we currently operate two complementary, proprietary technologies: high-throughput FISH for single-cell analysis, and a nucleotide-resolution telomere sequencing assay. Building on this foundation, we are extending the platform across additional hallmarks. Active programs include microbiome composition, profiled through shotgun metagenomics with metatranscriptomics in development, and mitochondrial activity at single-cell resolution, with a new assay under development for clinical-grade deployment.

02HALLMARKS

The hallmarks of aging provide the unifying biological framework of our platform. Originally described as twelve interconnected mechanisms shaping the onset, progression and heterogeneity of age-related disease, they have remained difficult to measure systematically in clinical settings. We treat them as measurable biological dimensions rather than research concepts, designing each of our tools to capture one or more hallmarks at a resolution compatible with clinical use. This framework allows individual biological insights to be combined into integrated, multi-hallmark assessments of patient biology.

03DATA

Our measurement tools are deployed in clinical studies across age-related disease, where they generate proprietary, structured datasets at scale. Each study is designed to capture hallmarks of aging in well-characterized patient populations, building longitudinal records that link biological measurement to clinical outcomes. Over time, these datasets accumulate into a unique clinical resource: high-resolution biological signatures tied to disease phenotypes, treatment trajectories and patient stratification. This resource powers our own diagnostic programs and forms the foundation of a long-term data asset relevant to pharmaceutical R&D.

04DIAGNOSTICS

From these datasets, machine learning surfaces biological fingerprints specific to each disease, revealing patterns that traditional diagnostics cannot resolve. Where these signatures align with hallmarks of aging dysfunction, they expose the underlying etiology in patients previously classified as idiopathic. This is the basis on which we develop our proprietary diagnostics: tests that move beyond symptom recognition to identify the biological cause of disease, supporting earlier intervention, more targeted treatment and better clinical decision-making in age-related conditions.

CLINICAL TRANSLATION

One sample. One workflow. Two outputs: clinical-grade diagnostics, and a structured biological resource for pharmaceutical R&D.